Anti-influenza H1N1/2009 vaccine in autoimmune rheumatic diseases patients
| Full text | |
| Author(s): Show less - |
Aikawa, Nadia E.
[1]
;
Campos, Lucia M. A.
[2]
;
Silva, Clovis A.
[2]
;
Carvalho, Jozelio F.
[2]
;
Saad, Carla G. S.
[2]
;
Trudes, Guilherme
[2]
;
Duarte, Alberto
[3]
;
Miraglia, Joao L.
[4]
;
Timenetsky, Maria do Carmo S.
[5]
;
Viana, Vilma S. T.
[2]
;
Franca, Ivan L. A.
[2]
;
Bonfa, Eloisa
[2]
;
Pereira, Rosa M. R.
[6]
Total Authors: 13
|
| Affiliation: | [1] Univ Sao Paulo, Fac Med, Pediat Rheumatol Unit, Div Rheumatol, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Pediat Rheumatol Unit, Fac Med, Hosp Clin, BR-01246903 Sao Paulo - Brazil
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Div Cent Lab, BR-01246903 Sao Paulo - Brazil
[4] Fundacao Butantan, Inst Butantan, Sao Paulo - Brazil
[5] Univ Sao Paulo, Inst Adolfo Lutz, Fac Med, Hosp Clin, BR-01246903 Sao Paulo - Brazil
[6] Univ Sao Paulo, Fac Med, Disciplina Reumatol, Div Infect Dis, BR-01246903 Sao Paulo - Brazil
Total Affiliations: 6
|
| Document type: | Journal article |
| Source: | JOURNAL OF RHEUMATOLOGY; v. 39, n. 1, p. 167-173, JAN 2012. |
| Web of Science Citations: | 34 |
| Abstract | |
Objective. To assess the immunogenicity and safety of non-adjuvanted influenza A H1N1/2009 vaccine in patients with juvenile autoimmune rheumatic disease (ARD) and healthy controls, because data are limited to the adult rheumatologic population. Method's. A total of 237 patients with juvenile ARD {[}juvenile systemic lupus erythematosus (JSLE), juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), juvenile scleroderma, and vasculitis] and 91 healthy controls were vaccinated. Serology for anti-H1N1 was performed by hemagglutination inhibition assay. Seroprotection rate, seroconversion rate, and factor-increase in geometric mean titer (GMT) were calculated. Adverse events were evaluated. Results. Age was comparable in patients and controls (14.8 +/- 3.0 vs 14.6 +/- 3.7 years, respectively; p = 0.47). Three weeks after immunization, seroprotection rate (81.4% vs 95.6%; p = 0.0007), seroconversion rate (74.3 vs 95.6%; p < 0.0001), and the factor-increase in GMT (12.9 vs 20.3; p = 0.012) were significantly lower in patients with juvenile ARD versus controls. Subgroup analysis revealed reduced seroconversion rates in JSLE (p < 0.0001), JIA (p = 0.008), JDM (p = 0.025), and vasculitis (p = 0.017). Seroprotection (p < 0.0001) and GMT (p < 0.0001) were decreased only in JSLE. Glucocorticoid use and lymphopenia were associated with lower seroconversion rates (60.4 vs 82.9%; p = 0.0001; and 55.6 vs 77.2%; p = 0.012). Multivariate logistic regression including diseases, lymphopenia, glucocorticoid, and immunosuppressants demonstrated that only glucocorticoid use (p = 0.012) remained significant. Conclusion. This is the largest study to demonstrate a reduced but adequate immune response to H1N1 vaccine in patients with juvenile ARD. It identified current glucocorticoid use as the major factor for decreased antibody production. The short-term safety results support its routine recommendation for patients with juvenile ARD. ClinicalTrials.gov; NCT01151644. (First Release Nov 15 2011; J Rheumatol 2012;39:167-73; doi:10.3899/jrheum.110721) (AU) | |
| FAPESP's process: | 10/10749-0 - Anti-influenza H1N1/2009 vaccine in autoimmune rheumatic diseases patients |
| Grantee: | Eloisa Silva Dutra de Oliveira Bonfá |
| Support type: | Regular Research Grants |